Adjuvant immunotherapy by levamisole in resectable lung cancer: A control study

Since 1976, a double blind study has been conducted to assess the value of levamisole as adjuvant treatment to surgery for non-small cell carcinoma of the lung. Fifty-one patients were evaluable with a minimal follow-up period of 1 yr. No difference could be observed between the two groups in the du...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of cancer Vol. 16; no. 12; pp. 1597 - 1601
Main Authors Van Houtte, P., Bondue, H., Rocmans, P., Michel, J., Wybran, J., Dalesio, O., Balikdjian, D., Vanderhoeft, P., Kenis, Y.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.12.1980
Subjects
Adult
Aged
Clinical Trials as Topic
Double-Blind Method
Female
Humans
Levamisole - therapeutic use
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - surgery
Male
Middle Aged
Postoperative Period
Online AccessGet full text

Cover

More Information
Summary:Since 1976, a double blind study has been conducted to assess the value of levamisole as adjuvant treatment to surgery for non-small cell carcinoma of the lung. Fifty-one patients were evaluable with a minimal follow-up period of 1 yr. No difference could be observed between the two groups in the duration of the survival and of the disease free survival. In cases of complete resection without any lymph node involvement, an increase of the free interval was observed. This was not statistically significant.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0014-2964
DOI:10.1016/0014-2964(80)90033-X